Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Corey Stephen Cutler, M.D.

Co-Author

This page shows the publications co-authored by Corey Cutler and Rizwan Romee.
Connection Strength

1.487
  1. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021 Sep 02.
    View in: PubMed
    Score: 0.248
  2. Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217.
    View in: PubMed
    Score: 0.242
  3. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
    View in: PubMed
    Score: 0.238
  4. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
    View in: PubMed
    Score: 0.232
  5. Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 Oct 06.
    View in: PubMed
    Score: 0.062
  6. Impact of Cryopreservation and Transit Times of Allogeneic Grafts on Hematopoietic and Immune Reconstitution. Blood Adv. 2021 Sep 28.
    View in: PubMed
    Score: 0.062
  7. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 Aug 26.
    View in: PubMed
    Score: 0.062
  8. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7.
    View in: PubMed
    Score: 0.060
  9. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
    View in: PubMed
    Score: 0.060
  10. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
    View in: PubMed
    Score: 0.058
  11. BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
    View in: PubMed
    Score: 0.057
  12. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539.
    View in: PubMed
    Score: 0.055
  13. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836.
    View in: PubMed
    Score: 0.053
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.